NCCN Guidelines Insights: Hepatobiliary Cancers, Version 2.2019

Featured Updates to the NCCN Guidelines

Restricted access

The NCCN Guidelines for Hepatobiliary Cancers provide treatment recommendations for cancers of the liver, gallbladder, and bile ducts. The NCCN Hepatobiliary Cancers Panel meets at least annually to review comments from reviewers within their institutions, examine relevant new data from publications and abstracts, and reevaluate and update their recommendations. These NCCN Guidelines Insights summarize the panel’s discussion and updated recommendations regarding systemic therapy for first-line and subsequent-line treatment of patients with hepatocellular carcinoma.

Provided content development and/or authorship assistance.

  • 1.

    Ryerson AB, Eheman CR, Altekruse SF, . Annual Report to the Nation on the Status of Cancer, 1975-2012, featuring the increasing incidence of liver cancer. Cancer 2016;122:13121337.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 2.

    Global Burden of Disease Liver Cancer Collaboration; Akinyemiju T, Abera S, . The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the Global Burden of Disease Study 2015. JAMA Oncol 2017;3:16831691.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 3.

    Fattovich G, Stroffolini T, Zagni I, . Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004;127(5 Suppl 1):S3550.

  • 4.

    Makarova-Rusher OV, Altekruse SF, McNeel TS, . Population attributable fractions of risk factors for hepatocellular carcinoma in the United States. Cancer 2016;122:17571765.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 5.

    Marchesini G, Bugianesi E, Forlani G, . Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003;37:917923.

  • 6.

    Takamatsu S, Noguchi N, Kudoh A, . Influence of risk factors for metabolic syndrome and non-alcoholic fatty liver disease on the progression and prognosis of hepatocellular carcinoma. Hepatogastroenterology 2008;55:609614.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 7.

    Blonski W, Kotlyar DS, Forde KA. Non-viral causes of hepatocellular carcinoma. World J Gastroenterol 2010;16:36033615.

  • 8.

    Volk ML, Marrero JA. Early detection of liver cancer: diagnosis and management. Curr Gastroenterol Rep 2008;10:6066.

  • 9.

    Llovet JM, Ricci S, Mazzaferro V, . Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378390.

  • 10.

    Cheng AL, Kang YK, Chen Z, . Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:2534.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 11.

    Bruix J, Raoul JL, Sherman M, . Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. J Hepatol 2012;57:821829.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 12.

    Cheng AL, Guan Z, Chen Z, . Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: subset analyses of the phase III sorafenib Asia-Pacific trial. Eur J Cancer 2012;48:14521465.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 13.

    Raoul JL, Bruix J, Greten TF, . Relationship between baseline hepatic status and outcome, and effect of sorafenib on liver function: SHARP trial subanalyses. J Hepatol 2012;56:10801088.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 14.

    Abou-Alfa GK. Selection of patients with hepatocellular carcinoma for sorafenib. J Natl Compr Canc Netw 2009;7:397403.

  • 15.

    Abou-Alfa GK, Schwartz L, Ricci S, . Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006;24:42934300.

  • 16.

    Abou-Alfa GK, Amadori D, Santoro A, . Safety and efficacy of sorafenib in patients with hepatocellular carcinoma (HCC) and Child-Pugh A versus B cirrhosis. Gastrointest Cancer Res 2011;4:4044.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 17.

    Pinter M, Sieghart W, Hucke F, . Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib. Aliment Pharmacol Ther 2011;34:949959.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 18.

    Hollebecque A, Cattan S, Romano O, . Safety and efficacy of sorafenib in hepatocellular carcinoma: the impact of the Child-Pugh score. Aliment Pharmacol Ther 2011;34:11931201.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 19.

    Kim JE, Ryoo BY, Ryu MH, . Sorafenib for hepatocellular carcinoma according to Child-Pugh class of liver function. Cancer Chemother Pharmacol 2011;68:12851290.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 20.

    Lencioni R, Kudo M, Ye SL, . First interim analysis of the GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib) non-interventional study [published correction appears in Int J Clin Pract 2012;66:912]. Int J Clin Pract 2012;66:675683.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 21.

    Chiu J, Tang YF, Yao TJ, . The use of single-agent sorafenib in the treatment of advanced hepatocellular carcinoma patients with underlying Child-Pugh B liver cirrhosis: a retrospective analysis of efficacy, safety, and survival benefits. Cancer 2012;118:52935301.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 22.

    Marrero JA, Lencioni R, Ye SL, . Final analysis of GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma [HCC] and Of its treatment with sorafenib [sor]) in >3000 sor-treated patients (pts): clinical findings in pts with liver dysfunction [abstract]. J Clin Oncol 2013;15(Suppl):31. Abstract 4126.

    • Search Google Scholar
    • Export Citation
  • 23.

    Miller AA, Murry DJ, Owzar K, . Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301. J Clin Oncol 2009;27:18001805.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 24.

    Eisenhauer EA, Therasse P, Bogaerts J, . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228247.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 25.

    Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005;42:12081236.

  • 26.

    Kudo M, Finn RS, Qin S, . Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 2018;391:11631173.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 27.

    Bruix J, Qin S, Merle P, . Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017;389:5666.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 28.

    Abou-Alfa GK, Meyer T, Cheng AL, . Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J Med 2018;379:5463.

  • 29.

    Zhu AX, Park JO, Ryoo BY, . Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol 2015;16:859870.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 30.

    Chau I, Peck-Radosavljevic M, Borg C, . Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: patient-focused outcome results from the randomised phase III REACH study [published correction appears in Eur J Cancer 2017;100:135–136]. Eur J Cancer 2017;81:1725.

    • Search Google Scholar
    • Export Citation
  • 31.

    Zhu AX, Kang YK, Yen CJ, . REACH-2: a randomized, double-blind, placebo-controlled phase 3 study of ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein (AFP) following first-line sorafenib [abstract]. J Clin Oncol 2018;36(Suppl):Abstract 4003.

    • Search Google Scholar
    • Export Citation
  • 32.

    Zhu AX, Finn R, Galle PR, . Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first-line sorafenib: pooled efficacy and safety across two global randomized Phase 3 studies (REACH-2 and REACH). European Society for Medical Oncology (ESMO). Ann Oncol 2018;29(Suppl 8):viii205–270.

  • 33.

    El-Khoueiry AB, Sangro B, Yau T, . Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 2017;389:24922502.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 34.

    Crocenzi TS, El-Khoueiry AB, Yau T, . Nivolumab (nivo) in sorafenib (sor)-naive and -experienced pts with advanced hepatocellular carcinoma (HCC): CheckMate 040 study [abstract]. J Clin Oncol 2017;35 (Suppl):Abstract 4013.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 35.

    Zhu AX, Finn RS, Edeline J, . Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol 2018;19:940952.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 36.

    Merck provides update on KEYNOTE-240, a phase 3 study of KEYTRUDA (pembrolizumab) in previously treated patients with advanced hepatocellular carcinoma [press release]. Kenilworth, NJ: Business Wire; February 19, 2019. Available at: https://www.mrknewsroom.com/news-release/oncology/merck-provides-update-keynote-240-phase-3-study-keytruda-pembrolizumab-previou.

  • 37.

    Qin S, Bai Y, Lim HY, . Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia. J Clin Oncol 2013;31:35013508.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 38.

    Qin S, Cheng Y, Liang J, . Efficacy and safety of the FOLFOX4 regimen versus doxorubicin in Chinese patients with advanced hepatocellular carcinoma: a subgroup analysis of the EACH study. Oncologist 2014;19:11691178.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 39.

    Zhu AX, Blaszkowsky LS, Ryan DP, . Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006;24:18981903.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 40.

    Siegel AB, Cohen EI, Ocean A, . Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol 2008;26:29922998.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 41.

    Thomas MB, Morris JS, Chadha R, . Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J Clin Oncol 2009;27:843850.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 42.

    Hsu CH, Yang TS, Hsu C, . Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma. Br J Cancer 2010;102:981986.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 43.

    Sun W, Sohal D, Haller DG, . Phase 2 trial of bevacizumab, capecitabine, and oxaliplatin in treatment of advanced hepatocellular carcinoma. Cancer 2011;117:31873192.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 44.

    Pishvaian MJ, Lee MS, Ryoo BY, . Updated safety and clinical activity results from a phase Ib study of atezolizumab + bevacizumab in hepatocellular carcinoma (HCC). Presented at the ESMO 2018 Congress; October 19–23, 2018; Munich, Germany.

  • 45.

    Cainap C, Qin S, Huang WT, . Linifanib versus sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial. J Clin Oncol 2015;33:172179.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 46.

    Kang YK, Yau T, Park JW, . Randomized phase II study of axitinib versus placebo plus best supportive care in second-line treatment of advanced hepatocellular carcinoma. Ann Oncol 2015;26:24572463.

    • PubMed
    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 7496 4053 372
PDF Downloads 2719 1596 112
EPUB Downloads 0 0 0